PAC1 Receptor Mediates Electroacupuncture-Induced Neuro and Immune Protection During Cisplatin Chemotherapy

Frontiers in Immunology

Yongming Guo¹  Luis Ulloa¹  Yangyang Liu²  Yi Guo²  Shanshan Li³  Jin Huang³  Yinan Gong³  Yuxin Fang³  Siru Qin³  Shanshan Lu³  Suhong Zhao³  Jiaqi Wang³  Shenjun Wang⁴  Zhifang Xu⁴  Bin Wang⁶ 

[1] Moxibustion and Tuina, Tianjin University of Traditional Chinese Medicine, Tianjin, China;National Clinical Research Center for Chinese Medicine Acupuncture and Moxibustion, Tianjin, China;Research Center of Experimental Acupuncture Science, Tianjin University of Traditional Chinese Medicine, Tianjin, China;;School of Acupuncture &School of Traditional Chinese Medicine, Tianjin University of Traditional Chinese Medicine, Tianjin, China;Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin’s Clinical Research Center for Cancer, Tianjin, China;

关键词: neuromodulation;    chemotherapy;    immunosuppression;    hematopoiesis;    neurotoxic;    electroacupuncture;   

DOI  :  10.3389/fimmu.2021.714244

来源: DOAJ

【 摘 要 】

Platinum-based chemotherapy is an effective treatment used in multiple tumor treatments, but produces severe side effects including neurotoxicity, anemia, and immunosuppression, which limits its anti-tumor efficacy and increases the risk of infections. Electroacupuncture (EA) is often used to ameliorate these side effects, but its mechanism is unknown. Here, we report that EA on ST36 and SP6 prevents cisplatin-induced neurotoxicity and immunosuppression. EA induces neuroprotection, prevents pain-related neurotoxicity, preserves bone marrow (BM) hematopoiesis, and peripheral levels of leukocytes. EA activates sympathetic BM terminals to release pituitary adenylate cyclase activating polypeptide (PACAP). PACAP-receptor PAC1-antagonists abrogate the effects of EA, whereas PAC1-agonists mimic EA, prevent neurotoxicity, immunosuppression, and preserve BM hematopoiesis during cisplatin chemotherapy. Our results indicate that PAC1-agonists may provide therapeutic advantages during chemotherapy to treat patients with advanced neurotoxicity or neuropathies limiting EA efficacy.

【 授权许可】

Unknown